Mutations Sample Clauses

Mutations a) If Customer finds, induces, observes, or discovers an Essentially Derived Variety (hereinafter “E.D.V.”) such as any mutation or sport in any Flowering Only Varieties or Finished Plant, then Customer shall report the E.D.V. immediately to Ball or its Agent by registered letter. The letter shall include, at a minimum, the name for the Flowering Only Variety or Finished Plant from which the E.D.V. has been induced, observed or discovered, and a brief description of the E.D.V. b) At the written request of the Ball/Agent, Customer shall immediately provide the Ball/Agent with sufficient material of the E.D.V. c) Ball or the third party owner of the Flowering Only Variety (hereinafter "Third Party") if the Flowering Only Variety is the subject of a third party license agreement, shall own all right, title and interest in the E.D.V. Customer hereby assigns all right, title, and interest in the E.D.V. to Ball or Third Party, if applicable. Customer agrees to cooperate with Ball or Third Party by executing any documents Ball or Third
Sample 1Sample 2See All (4)
AutoNDA by SimpleDocs
Mutations. If and to the extent Mutations of the SARS-CoV-2 virus arise [***]
Sample 1Sample 2
Mutations. The conserved residues in the NxxxNPxxY motif also seem to be very sensitive to mutation considering the behavior of the point mutants and our previous random mutagenesis results that did not identify any gain-of-function mutant by mutations in this region (Beukers et al., 2004a). Typically, homology models are based on the alignment of entire helical regions between rhodopsin and receptors with unknown structure. Loop areas are normally ignored or modeled based on databases of loop conformations. These models have been used to design experiments as well as to explain experimental data. We used the structure of bovine rhodopsin as a template to build a homology model of the human adenosine A2B receptor to guide the selection of amino acids for site-directed mutagenesis. The recent disclosure of the 3-D structure of the human þ2 adrenergic receptor enabled us to make a homology model based on this template too. A structural overlay was made to investigate the differences between the two models with respect to the regions of interest in this study. The following differences were identified, i) the angle between helix 7 and 8, ii) the number of residues to link helix 7 and 8, iii) the location and side chain orientation of residues in the NxxxNPxxY motif, and iv) the nature of the salt bridge between helix 1 and helix 7. These findings suggest that care should be taken to interpret experimental data based on a single model. Cherezov already pointed to the shortcoming of homology models generated from a single structural template, as the structural divergence between two receptors would be quite difficult to predict accurately using only one receptor as a template (Cherezov et al., 2007). His conclusion was drawn from a similarity comparison between the þ2 adrenergic receptor crystal structure and homology models of the þ2 adrenergic receptor based on the structure of bovine rhodopsin and which were substantiated with biochemical data (Bissantz et al., 2003; Furse and Lybrand, 2003; Gouldson et al., 2004). Since the latter models used bovine rhodopsin as a template, they are more similar to the rhodopsin rather than the real þ2 adrenergic receptor structure. Although all class A receptors share a similar backbone consisting of 7 transmembrane domains linked by extracellular and intracellular loops, each receptor has its own characteristics. Slight differences in the structure may result in significant differences in intramolecular interactions. For example, in...
Sample 1
Mutations. 1. The seller is entitled to make technically necessary changes to the sold goods without prior knowledge or knowledge of the purchaser. 2. Deviations of 10% of the ordered amount and in case of products that have been manufactured especially for the purchaser, deviations of 20%, are allowed. The seller will accordingly invoice the delivered amount to the purchaser. 3. Every delivery of a part of an ordered amount is considered as a separate transaction. The fulfillment or non-fulfillment of the delivery of a part of an ordered amount has no influence on the other parts of the order.
Sample 1
Mutations. Licensee shall promptly notify NNII of any mutation that appears in any Licensed Cultivar nursery stock in Licensee’s possession or under Licensee’s control. Licensee acknowledges that the ownership of, and title to, any such mutation is retained by WSU. NNII and its representatives shall have unlimited access to Licensee’s premises during normal business hours, upon reasonable notice, to inspect all trees, budwood, and scion wood of the Licensed Cultivar and to remove all mutated plant material.
Sample 1
Mutations a) If Licensee finds, induces, observes, or discovers an Essentially Derived Variety (hereinafter “E.D.V.”) such as any mutation or sport in any Licensed Product or Finished Plant, then Licensee shall report the E.D.V. immediately to the Licensor/Agent by registered letter. The letter shall include, at a minimum, the name for the Licensed Product or Finished Plant from which the E.D.V. has been induced, observed or discovered, and a brief description of the E.D.V. b) At the written request of the Licensor/Agent the Licensee shall immediately provide the Licensor/Agent with sufficient material of the E.D.V. c) Licensor or the third party owner of the Licensed Product (hereinafter "Third Party") if the Licensed Product is the subject of a third party license agreement, shall own all right, title and interest in the E.D.V. Licensee hereby assigns all right, title, and interest in the E.D.V. to Licensor or Third Party, if applicable. Licensee agrees to cooperate with Licensor or Third Party by executing any documents Licensor
Sample 1

Related to Mutations

  • Infectious Diseases The Employer and the Union desire to arrest the spread of infectious diseases in the nursing home. To achieve this objective, the Joint Health and Safety Committee may review and offer input into infection control programs and protocols including surveillance, outbreak control, isolation, precautions, worker education and training, and personal protective equipment. The Employer will provide training and ongoing education in communicable disease recognition, use of personal protective equipment, decontamination of equipment, and disposal of hazardous waste.

  • Immunizations (except for those preventive immunizations for routine use in children, adolescents, and adults that have in effect a recommendation from the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention);

  • Vaccinations Contractor understands, acknowledges, and agrees that, pursuant to Article II of the General Appropriations Act, none of the General Revenue Funds appropriated to the Department of State Health Services (DSHS) may be used for the purpose of promoting or advertising COVID-19 vaccinations in the 2024-25 biennium. It is also the intent of the legislature that to the extent allowed by federal law, any federal funds allocated to DSHS shall be expended for activities other than promoting or advertising COVID-19 vaccinations. Contractor represents and warrants that it is not ineligible, nor will it be ineligible during the term of this Contract, to receive appropriated funding pursuant to Article II.

  • Adverse Events Subsequent to the date hereof, there shall not have occurred any of the following: (i) a suspension or material limitation in trading in securities generally on the New York Stock Exchange, the NASDAQ National Market or the NASDAQ Global Market, (ii) a general moratorium on commercial banking activities in the People’s Republic of China or New York, (iii) the outbreak or escalation of hostilities involving the United States or the People’s Republic of China or the declaration by the United States or the People’s Republic of China of a national emergency or war if the effect of any such event specified in this clause (iii) in your reasonable judgment makes it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares on the terms and in the manner contemplated in the Prospectus, or (iv) such a material adverse change in general economic, political, financial or international conditions affecting financial markets in the United States or the People’s Republic of China having a material adverse impact on trading prices of securities in general, as, in your reasonable judgment, makes it impracticable or inadvisable to proceed with the public offering of the Shares or the delivery of the Shares on the terms and in the manner contemplated in the Prospectus.

  • Intercept and Referral Announcements 6.1 When a Customer changes its service provider from Verizon to KDL, or from KDL to Verizon, and does not retain its original telephone number, the Party formerly providing service to such Customer shall provide a referral announcement (“Referral Announcement”) on the abandoned telephone number which provides the Customer’s new number or other appropriate information, to the extent known to the Party formerly providing service. Notwithstanding the foregoing, a Party shall not be obligated under this Section to provide a Referral Announcement if the Customer owes the Party unpaid overdue amounts or the Customer requests that no Referral Announcement be provided. 6.2 Referral Announcements shall be provided, in the case of business Customers, for a period of not less than one hundred and twenty (120) days after the date the Customer changes its telephone number, and, in the case of residential Customers, not less than thirty (30) days after the date the Customer changes its telephone number; provided that if a longer time period is required by Applicable Law, such longer time period shall apply. Except as otherwise provided by Applicable Law, the period for a referral may be shortened by the Party formerly providing service if a number shortage condition requires reassignment of the telephone number. 6.3 This referral announcement will be provided by each Party at no charge to the other Party; provided that the Party formerly providing service may xxxx the Customer its standard Tariff charge, if any, for the referral announcement.

  • Medications Psychotropic medications and medications associated with treating a diagnosed mental health condition.

  • Vaccination and Inoculation ‌ (a) The Employer agrees to take all reasonable precautions to limit the spread of infectious diseases among employees, including in-service seminars for employees. Where the Employer or Occupational Health and Safety Committee identifies high risk areas which expose employees to infectious or communicable diseases for which there are protective immunizations available, such immunizations shall be provided at no cost to the employee. The Committee may consult with the Medical Health Officer. Where the Medical Health Officer identifies such a risk, the immunization shall also be provided at no cost. The Employer shall provide Hepatitis B vaccine, free of charge, to those employees who may be exposed to bodily fluids or other sources of infection. (b) An employee may be required by the Employer, at the request of and at the expense of the Employer, to take a medical examination by a physician of the employee's choice. Employees may be required to take skin tests, x-ray examination, vaccination, and other immunization (with the exception of a rubella vaccination when the employee is of the opinion that a pregnancy is possible), unless the employee's physician has advised in writing that such a procedure may have an adverse effect on the employee's health.

  • Intercept Devices 26.1.1.1 Local and federal law enforcement agencies periodically request information or assistance from local telephone service providers. When either Party receives a request associated with an End User of the other Party, it shall refer such request to the Party that serves such End User, unless the request directs the receiving Party to attach a pen register, trap-and-trace or form of intercept on the Party's facilities, in which case that Party shall comply with any valid request.

  • Developments I will make full and prompt disclosure to the Company of all inventions, discoveries, designs, developments, methods, modifications, improvements, processes, algorithms, databases, computer programs, formulae, techniques, trade secrets, graphics or images, and audio or visual works and other works of authorship related to the business of the Company (collectively “Developments”), whether or not patentable or copyrightable, that are created, made, conceived or reduced to practice by me (alone or jointly with others) or under my direction during the period of my employment. I acknowledge that all work performed by me for the Company is on a “work for hire” basis, and I hereby do assign and transfer and, to the extent any such assignment cannot be made at present, will assign and transfer, to the Company and its successors and assigns all my right, title and interest in all Developments made, conceived or reduced to practice by me (alone or jointly with others) that (a) relate to the business of the Company or any customer of or supplier to the Company or any of the products or services being researched, developed, manufactured or sold by the Company or which may be used with such products or services; or (b) result from tasks assigned to me by the Company; or (c) result from the use of premises or personal property (whether tangible or intangible) owned, leased or contracted for by the Company (“Company-Related Developments”), and all related patents, patent applications, trademarks and trademark applications, copyrights and copyright applications, and other intellectual property rights in all countries and territories worldwide and under any international conventions (“Intellectual Property Rights”). To preclude any possible uncertainty, I have set forth on Exhibit 1 attached hereto a complete list of Developments that I have, alone or jointly with others, conceived, developed or reduced to practice prior to the commencement of my employment with the Company that I consider to be my property or the property of third parties and that I wish to have excluded from the scope of this Agreement (“Prior Inventions”). If disclosure of any such Prior Invention would cause me to violate any prior confidentiality agreement, I understand that I am not to list such Prior Inventions in Exhibit 1 but am only to disclose a cursory name for each such invention, a listing of the party(ies) to whom it belongs and the fact that full disclosure as to such inventions has not been made for that reason. I have also listed on Exhibit A all patents and patent applications in which I am named as an inventor, other than those which have been assigned to the Company (“Other Patent Rights”). If no such disclosure is attached, I represent that there are no Prior Inventions or Other Patent Rights. If, in the course of my employment with the Company, I incorporate a Prior Invention into a Company product, process or machine or other work done for the Company, I hereby grant to the Company a nonexclusive, royalty-free, paid-up, irrevocable, worldwide license (with the full right to sublicense) to make, have made, modify, use, sell, offer for sale and import such Prior Invention. Notwithstanding the foregoing, I will not incorporate, or permit to be incorporated, Prior Inventions in any Company-Related Development without the Company’s prior written consent. This Agreement does not obligate me to assign to the Company any Development which, in the sole judgment of the Company, reasonably exercised, is developed entirely on my own time and does not relate to the business efforts or research and development efforts in which, during the period of my employment, the Company actually is engaged or reasonably would be engaged, and does not result from the use of premises or equipment owned or leased by the Company. However, I will also promptly disclose to the Company any such Developments for the purpose of determining whether they qualify for such exclusion. I understand that to the extent this Agreement is required to be construed in accordance with the laws of any state which precludes a requirement in an employee agreement to assign certain classes of inventions made by an employee, this paragraph 5 will be interpreted not to apply to any invention which a court rules and/or the Company agrees falls within such classes. I also hereby waive all claims to any moral rights or other special rights which I may have or accrue in any Company-Related Developments.

  • Enhancements No Enhancement shall be provided in respect of any Series of Notes, nor will any Enhancement Provider have any rights hereunder, as third-party beneficiary or otherwise, unless the Servicer has provided its prior written consent to such Enhancement, such consent not to be unreasonably withheld.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!